The VANHEALTHING Cryptofund of Biotech innovations is an absolutely unique investment platform: profits are combined with premier access to cutting-edge biotechnological projects that save and improve human lives.
The VANHEALTHING Cryptofund of biotech innovations is a unique investment platform, unlike any other currently in existence. They combine cutting-edge biotechnology projects, effective financial management and social responsibility. This creates a self-sustaining ecosystem of scientific teams, R&D infrastructure, and organizational capabilities. The latter are powered by using blockchain, software and more conventional methods.
The former two approaches are used where appropriate, without creating unnecessary dependencies within our infrastructure.
In other words, our system includes everything that a healthy (in every sense of the word) society needs to create, develop and implement effective bio- and medical technologies. The essence of the model developed by our Fund is a functional alternative to most traditional institutions (be they commercial, governmental or non-profit) that other products or services in healthcare.
VANHEALTHING unites numerous self-sufficient companies and products into a single team. Each of our portfolio projects deserves investments even if considered its own, but our goal is to use technological synergy within our ecosystem and streamline processes that usually fall victim to bureaucracy or inefficient planning. Their high level of effectiveness is based on our knowledge of all the stages of project development and implementation. They take care of all the management and support responsibilities, leaving the scientists to do what they do best – save and improve lives. As a result, what our Fund others is a better quality of life for everyone.
The VANHEALTHING Cryptofund of biotech innovations operates in one of the fields that will shape the world of tomorrow, alongside such areas as AThey and alternative energy. What sets us apart is our transparent management approach, humanitarian values, emphasis on the most advanced innovative projects, and a philosophy of easy access to technology: premier access for our investors and easily attainable access for future customers. Every new breakthrough may mean tens of thousands of lives improved or saved. Social responsibility is our Fund’s core value.
|“||September 2014: First angel investment into the Force project.
June 2015: The USP Capital venture fund is launched.
September 2015: First Successful Kickstarter campaign completed by our portfolio company.
November 2015: Successful cardio-screening of 22 433 patients in rural areas. The Platform 20k project is born.
Devember 2015: Plans for the word's first psychometer are formulated - a unique device for constant monitoring of an individual's psycho-emotional state.
January 2016: The TRL3 experiment for the world's first one-hand ECG sensor is successfully conducted.
February 2016: Incorporation of Platform 20k and Planexta Inc.
April 2016: Start of development on PRECISE - the automated ECG interpretation project.
September 2016: Start of development on the world's first sleeveless arterial blood pressure monitor with +- 5 mg Hg accuracy.
November 2016: Successful completion of the SenceBand crowdfunding campaign.
January 2017: SenceBand receives two CES 2017 awards in the biotechnologies and wearable devices categories.
March 2017: One of our portfolio companies is chosen for the Vertical accelerator (Finland), considered to be one of the world's best accelerators in digital health tech.
April 2017: One of our portfolio companies is chosen for the Alchemist accelerator (U.S.A.), considered to be one of the world's best accelerator programs. The digital beta of PRECISE is launched.
May 2017: Start of clinical trials for PRECISE.
July 2017: The Fund's portfolio increases to 12 companies - a major new milestone.
August 2017: Start of the Fund's transformation into a cruptocurrency fund.
September 2017: The Cryptofund's development strategy is finalized. Publication of a fundamental scientific paper on aging predictor analysis and the dynamic estimation of biological age.
October 2017: The Cryptofund's portfolio is created. The medical version of SenceBand is named among the top 20 remote assistance projects of 2017 by HealthcareTech Outlook.
November-December 2018: The Fund conducts a Roadshow for the purpose of engaging investors and partners for the Cryptofund.
January 2018: Establishment and registration of the Cryptofund.
February 2018: Creation of the Cryptofund's board of directors and investment strategy.
February - August 2018: Preparation for the ITO and coordination with regulators for the purpose of issuing tokens.
March 2018: Establishment of the Cryptofund's hedge-fund division for the purpose of liquidity management.
August 2018: Demonstration of successful technological and financial results by the Cryptofund's portfolio companies.
September 2018: Launch of our ITO.
October 2018: Portfolio companies begin invesment using gathered funds.
Launch of the first stage of our A.R.K. infrastructure project specifically - the initial laboratory construction phase.
November 2018: Payment of dividens to token owners.
November 2018: Launch of the final stage of the A.R.K. infrastructure project.
January 2019: Launch of new technological projects within the Cryptofund.
|Alexander Lobanov||Chief investment officer||https://www.linkedin.com/in/alexander-lobanov-02874b72/||5.8|
|Alexander Tulko||Head of asset management||https://www.linkedin.com/in/alexander-tulko-ba753b4/||5.8|
|Yaroslav Kologryvov||Managing partner of Vanhealthing||https://www.linkedin.com/in/yaroslav-kologryvov-37221927/||5.8|
|Eugene Nayshtetik||President of Planexta Inc.||https://www.linkedin.com/in/nayshtetik/||3.2|
|Maryna Moskovko||CEO of A.R.K||3.2|
|Valery Kanevsky||CEO of Institute of High Technologies||3.2|
|Yury Tymoshenko||CEO of VieGraph||https://www.linkedin.com/in/yury-tymoshenko-86685a84/||3.2|
|Timur Shemsedinov||CEO of Interactive Cloud||https://www.linkedin.com/in/shemsedinov/||7.3|
|Sergey Stirenko||Head of the R&D department of supercomputer calculations, AI and AR/VR||3.2|
|Victoria Ustimenko||Chief PR Officer||https://www.linkedin.com/in/victoria-ustimenko-7ba940a3/||5.8|
|Inna Malyukova||Founder and managing Partner of Sikorsky Challenge||3.2|
|Dr. Ben Goertzel||Advisor, SingularityNET, CEO||https://www.linkedin.com/in/bengoertzel/||3.2|
|Dr. Greg Colvin||Advisor, Ethereum Virtual Machine Inventor||https://www.linkedin.com/in/gregcolvin/||6.2|
|Ivan Danishevsky||Advisor, ESM.one, media holding||https://www.linkedin.com/in/faeton/||5.8|